A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/1997
11/05/1997	EP0804186A1 Indole diterpene alkaloid compounds
11/05/1997	EP0804184A1 USE OF $g(v)-GUANIDINOCARBOXYLIC ACID ESTERS
11/05/1997	EP0804182A2 Use of gabapentin in the treatment of anxiety and panic
11/05/1997	EP0804181A1 Method and composition for treating mammalian diseases caused by inflammatory response
11/05/1997	EP0804180A1 Method of inhibiting cathepsin k
11/05/1997	EP0804168A1 Taste masked composition containing a drug/polymer complex
11/05/1997	EP0804076A1 Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
11/05/1997	CN1164192A Multicatalytic protease inhibitors
11/04/1997	US5684044 Mixed with amphoteric or pseudoamphoteric agent
11/04/1997	US5683676 Canister containing aerosol formulations containing P134a and particulate medicaments
11/04/1997	US5683675 Method of treating retained pulmonary secretions
11/04/1997	CA2089607C Nutritional supplement for the elderly
10/1997
10/30/1997	WO1997040073A2 BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT HF-COLL-18/514cf) FOR INHIBITING THE GROWTH OF TUMOURS AND CAPILLARY PROFILERATIONS
10/30/1997	WO1997040066A1 Suppression of immune response via inhibition of cathepsin s
10/30/1997	WO1997040064A1 Human netrin-1
10/30/1997	WO1997040058A1 Flea protease proteins, nucleic acid molecules, and uses thereof
10/30/1997	WO1997039760A1 Combination therapy for treatment of erectile dysfunction
10/30/1997	WO1997039749A2 Method for the prevention and treatment of cachexia and anorexia
10/30/1997	WO1997039721A2 Methods and compositions for regulating t cell subsets by modulating transcription factor activity
10/30/1997	WO1997035989A3 Cyclic nucleotide phosphodiesterase
10/30/1997	DE19616486A1 Verfahren zur Senkung des Blutglukosespiegels in Säugern A method for lowering blood glucose levels in mammals
10/30/1997	CA2252643A1 Methods and compositions for regulating t cell subsets by modulating transcription factor activity
10/30/1997	CA2252581A1 Flea protease proteins, nucleic acid molecules, and uses thereof
10/30/1997	CA2251714A1 Suppression of immune response via inhibition of cathepsin s
10/30/1997	CA2250869A1 Combination therapy for treatment of erectile dysfunction
10/29/1997	EP0803256A1 Drug for relieving side effects caused by immunosuppressants
10/29/1997	EP0803249A2 Cholesterol lowering drink mix compositions
10/29/1997	EP0802972A1 Nucleic acid encoding neuropeptide y/peptide yy (y2) receptors and uses thereof
10/29/1997	EP0802801A2 Methods and compositions for treatment of solid tumors in vivo
10/29/1997	EP0802797A1 Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
10/29/1997	EP0802784A1 Nutrient medium for use as a culture medium for epidermal cells, and uses thereof
10/29/1997	EP0802783A1 Topical preparations containing l-arginine
10/29/1997	EP0802782A1 Prophylactic and therapeutic treatment of skin sensitization and irritation
10/29/1997	EP0802731A1 Prophylactic treatment of allergic contact dermatitis
10/29/1997	EP0639069B1 Galenic form for ocular administration and process for the preparation of same
10/29/1997	EP0637976B1 Medicament for disinfection of the oral cavity
10/28/1997	US5681860 Method of increasing expression of HLA, cell surface and TAA antigens of cells using 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol
10/28/1997	US5681853 Mixture with amphoteric compound
10/28/1997	US5681581 Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
10/28/1997	US5681577 Multiple action cold/sinus preparations
10/23/1997	WO1997039126A1 Novel rantes homolog from prostate
10/23/1997	WO1997039119A1 Mammalian genes involved in viral infection and tumor suppression
10/23/1997	WO1997039032A1 Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
10/23/1997	WO1997039022A1 Novel compounds
10/23/1997	WO1997039017A1 STREPTOCOCCUS PNEUMONIAE HISTIDYL tRNA SYNTHETASE
10/23/1997	WO1997039016A1 NOVEL LysS PROTEINS FROM STREPTOCOCCUS PNEUMONIAE
10/23/1997	WO1997039014A1 STREPTOCOCCUS PNEUMONIAE ASPARTYL tRNA SYNTHETASE
10/23/1997	WO1997039013A1 STREPTOCOCCUS PNEUMONIAE ALANYL tRNA SYNTHETASE
10/23/1997	WO1997038737A1 Oxidised cellulose and vitamin e blend for topical hemostatic applications
10/23/1997	WO1997038728A1 Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
10/23/1997	WO1997038724A1 New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
10/23/1997	WO1997038722A1 Novel compounds
10/23/1997	WO1997038721A1 Novel compounds
10/23/1997	WO1997038720A1 Novel compounds
10/23/1997	WO1997038719A1 Novel compounds
10/23/1997	WO1997038717A1 Novel compounds
10/23/1997	WO1997038716A1 Novel compounds
10/23/1997	WO1997038715A1 Novel compounds
10/23/1997	WO1997038714A1 Novel compounds
10/23/1997	WO1997038708A1 Modulating epithelial-mesenchymal interactions
10/23/1997	WO1997038704A1 Treatment of bone disorders with adrenomedullin
10/23/1997	WO1997038697A1 Sensitization of cells to radiation and chemotherapy
10/23/1997	WO1997038695A1 Dhea combination therapy
10/23/1997	WO1997038694A1 Combination therapy for reducing the risks associated with cardiovascular disease
10/23/1997	WO1997038689A2 Enteric-coated pharmaceutical compositions of mycophenolate
10/23/1997	WO1997038686A1 Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction
10/23/1997	WO1997038685A1 Use of an osmolyte in the preparation of a medicament for treating complications resulting from ischemia
10/23/1997	WO1997038675A1 New pharmaceutical composition with anaesthetic effect
10/23/1997	WO1997038664A2 A method of treating cancer
10/23/1997	WO1997034586A3 Device and method for treating ophthalmic diseases
10/23/1997	WO1997034137A3 Methods of the identification of pharmaceutically active compounds
10/23/1997	WO1997026918A3 Ligand directed enzyme prodrug therapy
10/23/1997	WO1997026862A3 Improved concentrated injection and infusion solutions for intravenous administration
10/23/1997	WO1997026853A3 Dna encoding galanin galr2 receptors and uses thereof
10/23/1997	WO1997025068A3 Mesothelin antigen and methods and kits for targeting it
10/23/1997	DE19615710A1 Verfahren zur Gewinnung und Anwendung eines biologisch aktiven Eiweisstoffes - Kollagenfragment HF-COLL-18/514cf - in partiell aufgereinigter und synthetischer Form aus Körperflüssigkeiten zur Beeinflussung des Zellwachstums und der Diagnose von Kollagenerkrankungen sowie der Osteoporose Methods for obtaining and application of a biologically active Eiweisstoffes - collagen fragment HF-COLL-18 / 514cf - in partially purified form from body fluids and synthetic for influencing the cell growth and the diagnosis of collagen diseases and osteoporosis
10/23/1997	CA2252228A1 Treatment of bone disorders with adrenomedullin
10/23/1997	CA2251972A1 Combination therapy for reducing the risks associated with cardiovascular disease
10/23/1997	CA2251955A1 A method of treating cancer
10/23/1997	CA2251818A1 Mammalian genes involved in viral infection and tumor suppression
10/23/1997	CA2251733A1 Dhea combination therapy
10/23/1997	CA2251716A1 Sensitization of cells to radiation and chemotherapy
10/23/1997	CA2251204A1 Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction
10/23/1997	CA2251115A1 Novel rantes homolog from prostate
10/23/1997	CA2251071A1 Use of an osmolyte in the preparation of a medicament for treating complications resulting from ischemia
10/23/1997	CA2224859A1 Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
10/22/1997	EP0801574A1 Modulation of integrin-mediated signal transduction
10/22/1997	EP0801572A2 Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin
10/22/1997	EP0801570A1 Formulations and methods for reducing skin irritation
10/22/1997	EP0801554A1 Formulations and methods for reducing skin irritation
10/22/1997	EP0679093B1 Methods of delivering agents to target cells
10/22/1997	CN1036196C 1,3-Oxatholane nucleoside analogues
10/21/1997	US5679828 Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
10/21/1997	US5679797 Retroviral protease inhibiting compounds
10/21/1997	US5679685 Accelerated release composition containing bromocriptine
10/21/1997	US5679650 Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
10/21/1997	US5679649 Inducing anesthesia, sedation, analgesia, hypothermia and reduced stress by administering effective amount of adenosine, adenosine-mono, di or triphosphates
10/21/1997	US5679374 Dispersion of lipid vesicles capable of penetrating into layers of skin and containing antimicrobial agents, n-(1-oxyl-2,2,6,6-tetramethyl-4-piperidyl)-n-dimethyl-n-hydro xyethylammonium iodide, antiinflammatory agents, retinol
10/21/1997	US5679354 Vaccine having an iscom-like structure comprising at least one lipid and one saponin and being free of incorporated antigens
10/16/1997	WO1997038100A1 Human cachexia associated protein

1 ... 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 ... 1151